Episodic disability questionnaire (EDQ) measurement properties among adults living with HIV in Canada, Ireland, United Kingdom, and United States
© 2024. The Author(s)..
BACKGROUND: The Episodic Disability Questionnaire (EDQ) is a generic 35-item patient-reported outcome measure of presence, severity and episodic nature of disability. We assessed the measurement properties of the Episodic Disability Questionnaire (EDQ) with adults living with HIV.
METHODS: We conducted a measurement study with adults living with HIV in eight clinical settings in Canada, Ireland, United Kingdom, and United States. We electronically administered the EDQ followed by three reference measures (World Health Organization Disability Assessment Schedule; Patient Health Questionnaire; Social Support Scale) and a demographic questionnaire. We administered the EDQ only 1 week later. We assessed the internal consistency reliability (Cronbach's alpha; > 0.7 acceptable), and test-retest reliability (Intra Class Correlation Coefficient; > 0.7 acceptable). We estimated required change in EDQ domain scores to be 95% certain that a change was not due to measurement error (Minimum Detectable Change (MDC95%)). We evaluated construct validity by assessing 36 primary hypotheses of relationships between EDQ scores and scores on the reference measures (> 75% hypotheses confirmed indicated validity).
RESULTS: Three hundred fifty nine participants completed the questionnaires at time point 1, of which 321 (89%) completed the EDQ approximately 1 week later. Cronbach's alpha for internal consistency ranged from 0.84 (social domain) to 0.91 (day domain) for the EDQ severity scale, and 0.72 (uncertainty domain) to 0.88 (day domain) for the EDQ presence scale, and 0.87 (physical, cognitive, mental-emotional domains) to 0.89 (uncertainty domain) for the EDQ episodic scale. ICCs for test-retest reliability ranged from 0.79 (physical domain) to 0.88 (day domain) for the EDQ severity scale and from 0.71 (uncertainty domain) to 0.85 (day domain) for the EDQ presence scale. Highest precision was demonstrated in the severity scale for each domain (MDC95% range: 19-25 out of 100), followed by the presence (MDC95% range: 37-54) and episodic scales (MDC95% range:44-76). Twenty-nine of 36 (81%) construct validity hypotheses were confirmed.
CONCLUSIONS: The EDQ possesses internal consistency reliability, construct validity, and test-retest reliability, with limited precision when administered electronically with adults living with HIV across in clinical settings in four countries. Given the measurement properties, the EDQ can be used for group level comparisons for research and program evaluation in adults living with HIV.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
BMC infectious diseases - 24(2024), 1 vom: 10. Jan., Seite 71 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
O'Brien, Kelly K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Disability evaluation |
|---|
| Anmerkungen: |
Date Completed 12.01.2024 Date Revised 10.02.2024 published: Electronic UpdateOf: Res Sq. 2023 Apr 05;:. - PMID 37066168 Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12879-023-08958-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366910132 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366910132 | ||
| 003 | DE-627 | ||
| 005 | 20240210233110.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12879-023-08958-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1287.xml |
| 035 | |a (DE-627)NLM366910132 | ||
| 035 | |a (NLM)38200425 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a O'Brien, Kelly K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Episodic disability questionnaire (EDQ) measurement properties among adults living with HIV in Canada, Ireland, United Kingdom, and United States |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2024 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateOf: Res Sq. 2023 Apr 05;:. - PMID 37066168 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: The Episodic Disability Questionnaire (EDQ) is a generic 35-item patient-reported outcome measure of presence, severity and episodic nature of disability. We assessed the measurement properties of the Episodic Disability Questionnaire (EDQ) with adults living with HIV | ||
| 520 | |a METHODS: We conducted a measurement study with adults living with HIV in eight clinical settings in Canada, Ireland, United Kingdom, and United States. We electronically administered the EDQ followed by three reference measures (World Health Organization Disability Assessment Schedule; Patient Health Questionnaire; Social Support Scale) and a demographic questionnaire. We administered the EDQ only 1 week later. We assessed the internal consistency reliability (Cronbach's alpha; > 0.7 acceptable), and test-retest reliability (Intra Class Correlation Coefficient; > 0.7 acceptable). We estimated required change in EDQ domain scores to be 95% certain that a change was not due to measurement error (Minimum Detectable Change (MDC95%)). We evaluated construct validity by assessing 36 primary hypotheses of relationships between EDQ scores and scores on the reference measures (> 75% hypotheses confirmed indicated validity) | ||
| 520 | |a RESULTS: Three hundred fifty nine participants completed the questionnaires at time point 1, of which 321 (89%) completed the EDQ approximately 1 week later. Cronbach's alpha for internal consistency ranged from 0.84 (social domain) to 0.91 (day domain) for the EDQ severity scale, and 0.72 (uncertainty domain) to 0.88 (day domain) for the EDQ presence scale, and 0.87 (physical, cognitive, mental-emotional domains) to 0.89 (uncertainty domain) for the EDQ episodic scale. ICCs for test-retest reliability ranged from 0.79 (physical domain) to 0.88 (day domain) for the EDQ severity scale and from 0.71 (uncertainty domain) to 0.85 (day domain) for the EDQ presence scale. Highest precision was demonstrated in the severity scale for each domain (MDC95% range: 19-25 out of 100), followed by the presence (MDC95% range: 37-54) and episodic scales (MDC95% range:44-76). Twenty-nine of 36 (81%) construct validity hypotheses were confirmed | ||
| 520 | |a CONCLUSIONS: The EDQ possesses internal consistency reliability, construct validity, and test-retest reliability, with limited precision when administered electronically with adults living with HIV across in clinical settings in four countries. Given the measurement properties, the EDQ can be used for group level comparisons for research and program evaluation in adults living with HIV | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Disability evaluation | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a Measurement | |
| 650 | 4 | |a Questionnaires | |
| 650 | 4 | |a Reliability | |
| 650 | 4 | |a Validity | |
| 700 | 1 | |a Erlandson, Kristine M |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Darren A |e verfasserin |4 aut | |
| 700 | 1 | |a Carusone, Soo Chan |e verfasserin |4 aut | |
| 700 | 1 | |a Vera, Jaime H |e verfasserin |4 aut | |
| 700 | 1 | |a Bergin, Colm |e verfasserin |4 aut | |
| 700 | 1 | |a Avery, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Bayoumi, Ahmed M |e verfasserin |4 aut | |
| 700 | 1 | |a Hanna, Steven E |e verfasserin |4 aut | |
| 700 | 1 | |a Harding, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Solomon, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Clair-Sullivan, Natalie St |e verfasserin |4 aut | |
| 700 | 1 | |a O'Shea, Noreen |e verfasserin |4 aut | |
| 700 | 1 | |a Murray, Carolann |e verfasserin |4 aut | |
| 700 | 1 | |a Boffito, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Da Silva, George |e verfasserin |4 aut | |
| 700 | 1 | |a Torres, Brittany |e verfasserin |4 aut | |
| 700 | 1 | |a McDuff, Kiera |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Aileen M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC infectious diseases |d 2001 |g 24(2024), 1 vom: 10. Jan., Seite 71 |w (DE-627)NLM11120089X |x 1471-2334 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:10 |g month:01 |g pages:71 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12879-023-08958-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 1 |b 10 |c 01 |h 71 | ||